Klein Matthew B. sold $185K of CLPT
Klein Matthew B. sold 16,000 shares of ClearPoint Neuro, Inc. (CLPT) at $11.59 ($0.19M total) on 2026-05-21.
How this was made
The 30-second read
Why it matters
Traders may briefly reassess sentiment around CLPT due to director selling, but there is no accompanying news on trials, revenue, financing, or corporate actions.
Market read
This is a disclosed insider sale; it can influence short-term sentiment but does not provide new fundamental information.
What to watch
No context on total compensation, tax obligations, or whether other insiders/funds are buying; also the sale size may be small relative to the company’s float.
Background
The article reports an SEC Form 4 insider transaction: director Matthew Klein sold 16,000 ClearPoint Neuro shares on 2026-05-21.
Ticker impact
ClearPoint Neuro director Matthew Klein sold 16,000 shares in an open-market transaction, disclosing $185,440 proceeds on SEC Form 4.
Likely limited/short-lived impact; any move would be driven by sentiment rather than new company-specific information.
The filing is an ownership-change disclosure without accompanying operational updates; absence of a stated 10b5-1 plan can increase attention but still lacks proof of negative fundamentals.
Market effects
Minimal; this is company-specific insider activity with no disclosed sector-wide catalyst.
None indicated.
None indicated.
Counterpoint
The sale could be routine liquidity/portfolio management rather than a bearish view, especially given no disclosed linkage to business performance.
Key entities
- issuerClearPoint Neuro, Inc.
Subject of the insider transaction disclosure (director Matthew Klein sold shares).
- insiderMatthew B. Klein
Director who executed the open-market sale; holdings after transaction were 46,935 shares.
